Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial.
Turner S, Cotton S, Wood J, Bell V, Raja EA, Scott NW, Morgan H, Lawrie L, Emele D, Kennedy C, Scotland G, Fielding S, MacLennan G, Norrie J, Forrest M, Gaillard EA, de Jongste J, Pijnenburg M, Thomas M, Price D.
Turner S, et al. Among authors: scott nw.
Lancet Respir Med. 2022 Jun;10(6):584-592. doi: 10.1016/S2213-2600(21)00486-0. Epub 2022 Jan 31.
Lancet Respir Med. 2022.
PMID: 35101183
Clinical Trial.